The phase 3 NRG Oncology GU005 trial of SBRT vs MH-IMRT for intermediate-risk prostate cancer had co-primary endpoints including disease control and patient-reported outcomes.

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

SBRT after radical prostatectomy without ADT improves prostate cancer BCRFS and appears to be a viable alternative to conventionally fractionated radiation therapy, a phase 2 trial finds. After ...

Researchers from UCLA have found a promising new way to help men with recurring prostate cancer live longer without their ...

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a radioligand therapeutics ...

MiraDx Announces New Research Conducted by UCLA and Other Academic Centers Presented at ASTRO 2025 that Confirms that Prostate Cancer Patients Identified as High-risk with PROSTOX™ ultra for SBRT ...

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT), a form of high-dose radiation delivered in just five sessions, after ...

A Biden spokeswoman confirmed the former president finished several weeks of radiation therapy treatment Monday.

NCCN Expands Cancer Genetic Risk Assessment Guidelines Updates to two genetic risk assessment guidelines now include prostate, endometrial, and gastric cancer to reflect the growing understanding of ...